Dr. O'Neil Discusses the Development of Biomarkers for CRC

Bert O’Neil, MD
Published: Friday, Aug 11, 2017



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

It is too early to state whether a biomarker will matter for combinations for the treatment of patients with CRC, explains O’Neil. Phase III data are needed to further investigate that question, but trials can be difficult to get started.

SELECTED
LANGUAGE


Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

It is too early to state whether a biomarker will matter for combinations for the treatment of patients with CRC, explains O’Neil. Phase III data are needed to further investigate that question, but trials can be difficult to get started.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x